摘要
目的:了解我院病区口服质子泵抑制剂(PPI)的使用情况,为临床安全、经济、高效用药提供参考。方法:对2009—2011年我院病区口服PPI的品种、销售金额、用药频度(DDDs)、限定日费用(DDC)进行统计分析。结果:2009—2011年我院病区口服PPI的用药量呈先升后降趋势。销售金额和DDDs排序埃索美拉唑镁肠溶片均居首位,奥美拉唑镁肠溶片(洛赛克MUPS,20 mg)排序居第2位;奥美拉唑肠溶片(10 mg)的DDDs呈稳步增长趋势,金额序号/DDDs序号为1.67,序号比最大,表明该药的使用频度较高,但其DDC却相对较低;兰索拉唑肠溶片从2010到2011年呈快速增长趋势(137%)。结论:我院病区口服PPI应用基本合理。
OBJECTIVE: To investigate the use of oral proton pump inhibitors (PPI) in the inpatients of Peking University Shenzhen Hospital so as to provide reference for clinical safe, economical and effective use of PPI. METHODS : The total consumption sum, the DDDs and the defined daily cost (DDC) of oral PPI in the inpatients of our hospital from 2009 to 2011 were given a statistical analysis. RESULTS: The total consumption amount of oral PPIin the inpatients of our hospital from 2009 to 2011 showed an increase followed by a decrease. Esomeprazole magnesium enteric-coated tablets topped the list in terms of both consumption sum and DDDs, followed by omeprazole magnesium enteric-coated tablets (losec mups, 20 mg). The DDDs of omeprazole (10 rag) showed a steady growth trend. The ratio of the consumption sum serial number to the DDDs serial number of enteric-coated tablets was the maximum at 1.67, indicating the highly frequent use of this drug; however, which had low DDC. The DDDs of lansoprazole increased rapidly by 137% in 2011 over the previous year. CONCLUSION: The use of oral PPI in the inpatients of our hospital was reasonable on the whole.
出处
《中国医院用药评价与分析》
2012年第6期509-511,共3页
Evaluation and Analysis of Drug-use in Hospitals of China